Boothbay Fund Management, LLC Apellis Pharmaceuticals, Inc. Put Options Transaction History

Boothbay Fund Management, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $1.69 Million - $2.41 Million	58,600 New	58,600 $1.69 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $4.53 Million - $5.92 Million	81,700 New	81,700 $4.8 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $4.03 Million - $15.2 Million	-170,300 Reduced 95.35%	8,300 $315,000
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $13.7 Million - $16.7 Million	178,600 New	178,600 $16.3 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $2.88 Million - $4.06 Million	-66,500 Reduced 68.35%	30,800 $1.59 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $2.98 Million - $4.63 Million	66,500 Added 215.91%	97,300 $6.65 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $166,662 - $254,364	-4,700 Reduced 13.24%	30,800 $1.57 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $43,960 - $97,776	1,400 Added 4.11%	35,500 $1.17 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $1.39 Million - $2.21 Million	34,100 New	34,100 $2.16 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.